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Abstract
Ligand-receptor binding is of utmost importance in several biologically related disciplines.
Ligand binding assays (LBA) use the high specificity and high affinity of ligands to detect,
target or measure a specific receptors. One particular example of ligand binding assays are
Antibody conjugated Nanoparticles (AcNPs), edge-cutting technologies that are present in
several novel biomedical approaches for imaging, detection and treatment of diseases.
However, the nano-confinement in AcNPs and LBA nanostructures introduces extra com-
plexity in the analysis of ligand-receptor equilibriums. Because antibodies are large volumi-
nous ligands, the effective affinity in AcNPs is often determined by antibody orientation and
surface coverage. Moreover, antibodies have two binding sites introducing an extra ligand-
receptor binding equilibrium. As consequence of all this, experimental or theoretical studies
providing a guidelines for the prediction of the binding behavior in AcNPs are scarce. In this
work, we present a set of theoretical calculations to shed light into the complex binding
behavior of AcNPs and its implications in biomedical applications. To investigate the ligand-
receptor binding on AcNPs, we have used a molecular theory that predicts the probability of
different molecular conformations of the system depending on the local environment. We
have considered two different pathways for designing these devices: covalently conjugated
antibodies and streptavidin-biotin conjugated antibodies. We also explore the effects of sur-
face coverage, bulk concentrations, nanoparticle size and antibody-antigen affinity. Overall,
this work offers a series of theoretical predictions that can be used as a guide in the design
of antibody conjugated nanoparticles for different applications.
Introduction
The binding between a ligand and its receptor is the main area of research in several biologi-
cal related disciplines. Ligand-receptor binding is ubiquitous in many biological processes,
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including immune reactions, signaling, opening of ion channels and gene activity [1–4]. In
the pharmaceutical industry, around 70% of the total sales of drugs to treat cancer [5] and
autoimmune diseases [6] are therapies based on the binding of antibodies (the ligands) to
specific receptors. The main feature of ligand-receptor binding that makes this interaction
so attractive for a variety of applications is that it displays high specificity and high affinity.
For example, antibodies only bind strongly to their respective complementary epitopes
(high selectivity), with typical antibody-antigen dissociation constants (Kd) in the range of
10−8 to 10−11 M (high affinity) [7]. Due to these characteristics the biomedical research field
has introduce several techniques that exploit ligand-receptor interactions. In particular, we
can mention ligand-binding assays (LBA) that use ligands to detect, to target or to measure a
specific receptor [1–3].
During the last decade, the production of LBA combined with nanoparticles (NPs) has
increased due to the potential for in-vivo and in-vitro imaging and detection of different ana-
lytes, as well as for specific therapies such as thermal-ablation, gene therapy or localized drug
delivery with nano-carriers [8–13]. However, nanoparticle mediated ligand-receptor binding
displays a particularly complex behavior that arises from the confinement of the molecular
species on a small surface. The chemical equilibrium between ligands and receptors can be
locally displaced according to the inhomogeneous concentration of the species, which results
in an effective affinity that highly depends on the local environment and the nature of the con-
finement. For that, predicting of the outcome behavior of LBA in nano-structures represents a
challenging task that requires the collection of extensive experimental data and/or theoretical
calculations.
The vast majority of novel LBA platforms include NPs modified with antibodies as ligands
molecules. These antibody-conjugated nanoparticles (AcNPs) take advantage of the high affin-
ity and selectivity of antibodies [5, 6, 14] in combination with the large surface-area/volume
ratio offered by NPs. However, as mentioned before, confinement modifies the effective anti-
body-receptor affinity, which is highly dependent on the local environment. To add an extra
layer of complexity, the effective affinity in AcNPs is often determined by the orientation and
density of antibodies on the surface, since these molecules are large voluminous ligands. More-
over, antibodies have two possible binding sites, which introduces an additional ligand-recep-
tor binding equilibrium.
Some experimental works on AcNP- and LBA-related systems have investigated the bind-
ing behavior as a function of antibody surface coverage [15–20]. These studies have shown
that AcNPs ligand-receptor binding displays a non-monotonic behavior as a function of the
number of antibodies on the surface. As the surface coverage of antibodies is increased, the
amount of captured antigen reaches a maximum at low surface coverage and then decays
into a plateau at high surface coverage. This non-monotonic behavior in the binding capac-
ity is generally hypothesized as being the consequence of the increasing influence of surface
crowding. Some theoretical works have focused on understanding the concentration depen-
dence of this binding [21], but they have not conclusively explained the non-monotonic
behavior in AcNPs.
Ligand-receptor binding in LBA and AcNPs is favored by the decrease in chemical free
energy, particularly when the affinity is high. In contrast, on crowded surfaces with volumi-
nous ligands, several entropic contributions to the free energy oppose this binding (e.g., the
entropic loss due to ligand immobilization). This decrease in entropy upon binding is particu-
larly relevant if the nano-environment near the surface is sufficiently crowded. In this work,
we will show that ligand-receptor binding with voluminous molecules such as antibodies
results from the competition between binding and opposing entropic effects induced by sur-
face crowding.
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Our approach to study this problem is to use a molecular theory based on the minimization
of the total free energy of the system. This molecular theory [22–26] take into account the con-
formations and chemical information of each of the molecules involved, including a detailed
description of the antibody three dimensional structure. As a result, we can calculate the ther-
modynamic properties of the system, the density profiles and the degree of binding of the dif-
ferent species on or near the surface. Previous works have used this theory to investigate the
behavior of ligand-receptor binding in tethered polymer layers [23, 24] showing good agree-
ment with a similar experimental findings [20, 27] Moreover, this theory has shown very good
agreement with experimental results in different scenarios[22–26, 28].
Here we use this molecular theory to investigate ligand-receptor binding of LBA and in par-
ticular of AcNPs. We study the molecular origin of the non-monotonic binding behavior in
AcNPs and predict the optimal surface coverage for different system configurations as a func-
tion of several variables. Moreover, there are different conjugation strategies to anchor anti-
bodies to AcNPs [29], some relying on a second ligand-receptor equilibrium with high affinity
(i.e., biotinylated antibodies that bind to streptavidin on the nano-surface). Though strong,
this second binding is not permanent. To investigate this possibility, we have evaluated two
different designs: a) AcNPs with antibodies covalently grafted to the surface, and b) AcNPs
with antibodies conjugated through streptavidin-biotin binding. Fig 1 schematizes the differ-
ent systems considered in the present work, as well as the coarse-grained molecular model
used to calculate results with our theory. More details about the theoretical approach can be
found in method section and in the supporting information (S1 Text).
In the following sections we will present and discuss the results obtained in our calculations
and show the dramatic effect that voluminous ligands have in determining ligand-receptor
equilibrium in confined environments. Furthermore, the following set of results provides a
theoretical platform for facilitating the interpretation of experimental findings in similar com-
plex scenarios and can help in the rational design of biomedical applications of LBA and
AcNPs.
Methods
Our theoretical methodology is based on a previously developed molecular theory [15–20].
The predictions of this theory have been shown to be in good agreement with experimental
observations for ligand-receptor binding in polymer layers [20, 23, 24, 27]. This method
explicitly accounts for the volume and conformations of the molecular species including the
antibody, antigen and antibody-antigen complexes, and predicts the amount of binding
depending on local environment. Application of this theory requires the input of the different
molecular conformations of the system. To describe the antibody, we use a coarse-grained
model based on the crystallographic data of anti-HIV-1 b12 monoclonal antibody [30] and its
complex with HIV gp120 [31]. For the binding of two antigens to the antibody we have used a
ratio affinity/avidity extracted from experimental results on b12 antibody [32]. The dissocia-
tion constant range is based on the experimental work of Landry et al [7] that suggest a Kd
range of 10−8 to 10−11 M for different antibody/antigens. Each amino acid in the structure is
represented by a single bead of 0.6 nm diameter, centered at the alpha carbon of the corre-
sponding residue. The spacer conformation is based on a coarse-grain model of poly(ethylene-
glycol) (PEG) where each bead (diameter = 0.6 nm) represents a monomeric unit (EG). The
antibody structure is fixed in its initial conformation obtained from the PDB, but has full
three-dimensional rotational and translational freedom. Conformations of the spacer are gen-
erated using a rotational isomeric state model [33]. Streptavidin is considered as punctual
binding sites on the surface having no volume.
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Fig 1. Scheme of the systems investigated in this work. a) Antibody conjugated nanoparticle with
antibodies covalently bonded to the nanoparticle. b) Antibody conjugated nanoparticle with antibodies bonded
through streptavidin-biotin. *) Scheme of the coarse grain model of the antibody b12 (cyan) having a 50 units
spacer and an antigen gp120 bound (blue).
https://doi.org/10.1371/journal.pone.0185518.g001
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The general analytical form of the Helmholtz free energy used to describe this system is the
following:
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The different terms in this equation account for: the translational entropy of water (first
term), the translational and conformational (rotational) entropy of the species in solution as
well as their self-energies (second term), the conformational entropy of those species bound to
the surface (third term), and the mixing entropy and self-energy of the species bound to the
surface (fourth term). The subscripts represent the different species: unbound antibody (A),
antibody + 1 antigen (Aa), antibody + 2 antigens (Aaa), streptavidin (S) and water (w). ρi(r) is
the local density of species “i” in the element of volume of thickness dr at a distance r from the
center of the spherical nanoparticle. The volume of a water molecule is vw. The different
molecular conformations of a species are denoted by αi
NP for molecules bound to the nanopar-
ticle surface and αi
sol for free molecules in the solution. Pi(αiNP) is the probability of having a
molecule of species “i” in a conformation “αi
NP” attached to the NP. Ns is the number of active
sites on surface (streptavidin or antibody). fiNP is the fraction of active surface sites occupied
by the specie “i”. The quantity μiNP0 and μiNP0 are the standard chemical potentials of the
bound and free specie “i”, respectively, and β = 1/kBT where kB is the Boltzmann constant and
T the temperature. In this description there are no explicit interactions included and all the
attractions are grouped in terms of dissociation constants Kd. The repulsive part of the interac-
tion is taken into account as the excluded volume occupied by different species.
Functional minimization of the free energy yields expressions for the each of above-
described functions that depend on one interaction potential, the local osmotic pressure. This
minimum must satisfy local incompressibility of the fluid and constant chemical potential of
the species in solution. To solve this constrained optimization, we introduce Lagrange multi-
pliers. The local osmotic pressure is obtained by numerically solving the incompressibility con-
straint at each distance (in the solution) from the center of the nanoparticle. Calculations are
performed in radial coordinates (r), and space is discretized in layers of thickness dr. Once we
obtain the interaction potential, all the functions that compose the free energy are determined.
Then we can calculate the number antigen/antibodies adsorbed as a function of the number of
binding sites on the surface (or the number of antibodies grafted to the surface). Moreover,
any thermodynamic quantities of interest can be derived from the free energy. Structural prop-
erties can be calculated using the probability distribution of the different molecular conform-
ers. More specific details of the theory and mathematical procedure employed are provided in
the supporting information (S1 Text).
Our calculations are performed at constant chemical potential (constant concentration).
Thus, in order to investigate the degree binding, we have to include the bulk species of all the
possible complexes. However, in the covalently conjugated and streptavidin conjugated
AcNPs, we have different amounts of possible complexes. Nevertheless, in order to compare
the binding behavior in the two AcNP architectures, some results are plotted as a function of
the number of bound antibody-antigen pairs on surface. Moreover, in the streptavidin
Behavior of ligand binding assays with crowded surfaces
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conjugation scheme, the equilibrium concentration of each species in solution is obtained
through solving the chemical equilibrium for the initial conditions. These initial conditions
yield similar concentrations as those considered for the system with covalently bonded
antibodies.
Results
a) AcNP with antibodies covalently bonded
Our first ligand-receptor system consists of a spherical NP with a fix number of antibodies
(ligands) attached to the surface immersed in an antigen (receptor) solution of controlled con-
centration. Antibodies are grafted to the surface with a chemical bond. The variables that we
control on the theoretical model are: spacer, antibody/antigen dissociation constant (Kd), bulk
concentration and antibody surface coverage. To analyze relevant concentrations of antigen,
we consider two different experimental situations. Since we are using the molecular architec-
ture of anti-HIV-1 antibody, we use an antigen (gp120) bulk concentration of 20 pM, in range
with the observed concentrations in serum at the acute stage of HIV infection [34, 35]. On the
other hand, to illustrate a more concentrated environment like in vitro systems we have used a
concentration of 100 nM of antigen. The NP radius used in these calculations is 50 nm, which
is in the typical range for polymeric conjugated nanoparticles.
In Fig 2, we plot the number of antigens captured by the AcNP as a function of the surface
coverage of antibodies, for an antigen bulk solution of 20 pM (upper panels, Fig 2A and 2B)
and 100 nM (lower panels, Fig 2C and 2D) respectively. This functionality has been evaluated
for two spacer lengths: 50 segments (left panels, Fig 2A and 2C) and no spacer (right panels,
Fig 2B and 2D), and for 3 different antibody/antigen dissociation constants (different color
lines). System behavior is completely different in all the studied possibilities (Fig 2 panels A to
D). This is an indication of the complexity of ligand-receptor equilibrium at the surface of the
AcNPs. At low antigen bulk concentration (Fig 2A and 2B; 20 pM antigen), only antibodies
with a very high affinity (Kd = 10-11M) can capture antigen molecules. Antigen-antibody pairs
with such strong affinity are not frequent in nature [7], which implies that a wide range of
applications, these AcNPs will not bind to any receptors at this concentration. Fig 2B displays
the behavior at low antigen bulk concentration without a spacer, and Fig 2A does with the
addition of a spacer of 50 segments. In Fig 2A shows the presence of a maximum at low surface
coverage. This maximum is the result of the competition between ligand-receptor binding and
conformational entropy of species on the surface. As the number of antibodies on the surface
of the AcNP increases, as many as possible ligand-receptor pairs bind. The maximum is
reached when adding more antibodies on surface significantly reduces the conformational
possibilities of the system. If we continue adding more antibodies to the surface, the number
of bound ligand-receptor pairs decreases to an approximately constant value (plateau), show-
ing the point where adding more antibodies does not increase the amount of bounds pairs on
the AcNP.
Introducing a spacer slightly increase the amount of bound pairs on the AcNP (Fig 2A and
2B). The function of the spacer is to increase the conformational possibilities of the antibodies
on the surface. This conformational gain is due to the flexibility of the spacer leading to an
increment in the available volume for binding, which can occur at different distances from the
surface. Due to this entropic effect, the spacer (Fig 2A) enhances the presence of the maximum
observed at low surface coverage.
The addition of a spacer considerably increases the amount of bound pairs on the AcNP
(compare Fig 2C and 2D). As we have previously noted in Fig 2A, spacer presence leads to a
maximum in the amount of bound pairs at low surface coverage. The maxima in Fig 2C are
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also shifted to higher surface coverage as we increase the antigen-antibody affinity. These two
features are the result of the further displacement of the ligand-receptor equilibrium condi-
tions towards the bound state that occurs nears the surface when increasing the receptor bulk
concentration.
One of the advantages of our molecular theory is that we can obtain information about the
amount of each species on the surface: unbound antibody, antibody bound to one antigen and
antibody bound to two antigens (one in each Fab domain). We are considering only monoclo-
nal antibodies; then the possible binding events are one antigen in each Fab domain (two
ligand-receptor equilibriums). In Fig 3, we plot the contribution of each species and the total
number of active antibodies on surface at high antigen bulk concentration (100 nM) and a 50
monomer spacer for Kd = 10−9 M (Fig 3A) and Kd = 10−11 M (Fig 3B). Fig 3 represent the
Fig 2. Captured antigen as a function of antibody surface coverage on AcNP with antibodies covalently conjugated. The
different colors represent different antibody/antigen Kd values. A) Antigen bulk concentration = 20 pM and spacer of 50 monomers.
B) Antigen bulk concentration = 20 pM and no spacer. C) Antigen bulk concentration = 100 nM and spacer of 50 monomers. D)
Antigen bulk concentration = 100 nM and no spacer.
https://doi.org/10.1371/journal.pone.0185518.g002
Behavior of ligand binding assays with crowded surfaces
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Fig 3. Number of unbound antibodies (0 ant.), antibodies bound to one antigen (1 ant.), antibodies
bound to two antigens (2 ant.) and total active antibodies (total) on surface, as a function of the
surface coverage in a covalently bonded AcNP. A) Antigen bulk concentration = 100 nM, 50 monomer
spacer, Kd = 10−9 M. B) Antigen bulk concentration = 100 nM, 50 monomer spacer, Kd = 10−11 M.
https://doi.org/10.1371/journal.pone.0185518.g003
Behavior of ligand binding assays with crowded surfaces
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same conditions as the red and green curves of Fig 2C. The dashed straight lines represent the
total number of antibodies bound to antigens. In Fig 3A (Kd = 10−9 M) we observe that anti-
bodies with two antigens are only present at low surface coverage (Fig 3 green lines). These are
the complexes that occupy the largest volume. When surface crowding increases, antibodies
with two antigens become the least favorable species due to the high entropic cost of crowding.
The species predominantly contributing to the antigen capture capability as shown in Fig 3A is
the antibodies with one antigen attach to the fab domain (red line curve). The plot also shows
that the number of antibodies with one antigen grows almost linearly with surface coverage
until reaching the conditions where crowding starts to affect binding. Maximum binding
occurs at approximately 0.00159 antibodies/nm2. After reaching this maximum, the amount of
antibodies with one antigen shows a plateau. At the same time, as we increase the surface cov-
erage we are only adding to the surface antibodies that will remain unbound (Fig 3 black line).
A similar behavior can be observed in Fig 3B at Kd = 10−11 M, but the shape and position of
the maxima are shifted to higher surface coverage. The maximum for antibodies with one anti-
gen is displayed at approximately 0.003 antibodies/nm2. As mentioned before, a lower Kd
leads to a more pronounced non-monotonic effect. Interestingly, Fig 3A and 3B show similar
populations of antibodies with two antigens. This indicates that despite the gain in chemical
free energy, the entropic cost of having two antigens attached to an antibody is very high, and
not even reducing the Kd (increment in affinity) two orders of magnitude substantially
enhances the presence of this molecular complex.
Our theoretical approach offers the possibility of analyzing the probability of the different
molecular conformations. Using such information allows for calculating different quantities to
describe molecular reorganization on the surface of the AcNP. Fig 4 shows the average value of
the position of the center of mass of the antibody (<RCOM>). The conditions are the same as
those of Fig 3, bulk antigen concentration of 100 nM and a spacer having 50 monomeric units.
In Fig 4A, Kd = 10-9M and Kd = 10-11M in Fig 4B. The center of mass position gives informa-
tion about how stretched or compacted are the molecules on the surface as a function of sur-
face coverage. Higher values of<RCOM> represent antibodies far from the surface in more
stretched conformations of the spacer. We observe in Fig 4A that antibodies bound to two
antigens (green line) are the ones that remain farthest from the surface. As aforementioned,
this complex occupies the largest volume. Then the optimal conformations of this species are
stretched because more compact conformations would lead to high steric repulsions.
Unbound antibodies (black line), in contrast, remain in relatively collapsed conformations
with little variation in the position of their center of mass.
The conformations of antibodies with one antigen (red line curve in Fig 4A), remain rela-
tively collapsed at low surface coverage, while at high surface coverage they are found in more
stretched conformations due to crowding effects. Interestingly, both antigen-antibody com-
plexes, with one and two antigens, undergo a transition from compact to stretched conforma-
tions around the positions (surface coverage) of the their respective maximal binding (see Fig
3A). This implies that those maxima are reached when crowding induces the transition from
collapsed to stretched conformations. Looking at Fig 3A, we see that antibodies with two anti-
gens vanish when more than ~75 antibodies are on surface, which is due to the high entropic
loss of having fully stretched conformations. The features of the above described conforma-
tional behavior of surface antibodies are similar for different binding affinities, the difference
being the position of the transition from collapsed to stretched conformations. In Fig 2C, we
show that a stronger binding affinity results in the displacement of maximum binding towards
higher antibody surface coverage. This occurs because the decrease in chemical free energy
upon binding is higher for antibodies for antigens with stronger affinities, which decreases the
relative entropic penalty of surface reorganization. For stronger binding affinities, the
Behavior of ligand binding assays with crowded surfaces
PLOS ONE | https://doi.org/10.1371/journal.pone.0185518 September 28, 2017 9 / 21
Fig 4. Covalent bonded AcNP. Averaged center of mass of unbound antibodies (0 ant.), antibodies bound to
one antigen (1 ant.), antibodies bound to two antigens (2 ant.) as a function of the surface coverage. A)
Antigen bulk concentration = 100 nM, spacer 50 monomers, Kd = 10−9 M. B) Antigen bulk concentration = 100
nM, spacer 50 monomers, Kd = 10−11 M.
https://doi.org/10.1371/journal.pone.0185518.g004
Behavior of ligand binding assays with crowded surfaces
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transition from compacted-to-stretched conformations occurs at higher surface coverage, thus
shifting the position of the maximum binding capacity of the AcNP to higher surface coverage
as well.
We next analyze the role of bulk concentration of antigen and nanoparticle radius in the
binding of antigens. Fig 5 presents results for an AcNP with covalently conjugated antibodies,
with a spacer of 50 monomers and Kd = 10-9M, for different bulk concentrations of antigen
(Fig 5A) and different NP radius (Fig 5B). In this plot, dashed arrows indicate the direction in
which either the concentration or the radius is increased.
Fig 5. Captured antigen per area as a function of antibody surface coverage. Covalent bonded AcNP,
spacer 50 monomers, Kd = 10−9 M. A) For different antigen bulk concentrations. AcNP radius = 50 nm. B) For
different AcNP radius. Inset in panel B) are same data but the captured antigen normalized by the area of the
NP. Red and black dashed lines, in the inset, represent the ideal situation of all the antibodies bound to two or
one antigen respectively. Antigen bulk concentration = 100 nM. Triangle symbols represent the set of
conditions used in this paper for the rest of the calculations.
https://doi.org/10.1371/journal.pone.0185518.g005
Behavior of ligand binding assays with crowded surfaces
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Fig 5A shows the influence of bulk concentration of antigen on the ligand-receptor binding.
As we increase this bulk concentration, the non-monotonic binding behavior (maximum)
enhances. This effect is similar to what occurs upon increasing the antibody-antigen affinity
(Fig 2C). A higher bulk concentration displaces chemical equilibrium to favor bound pairs.
Namely, raising the bulk concentration increases the chemical potential of the solution favor-
ing binding. However, at a given surface coverage crowding effects start to play an important
role (maximum binding). After this condition, many conformations that do not optimize vol-
ume become unfavorable (binding displays a plateau).
Fig 5B shows the dependence of the amount of bound pairs on the nanoparticle radius.
AcNP curvature strongly influences the non-monotonic binding behavior. This response can
be interpreted in terms of crowding. For large AcNP radius, the surface is locally planar, which
limits the conformational possibilities. In contrast, for smaller AcNP radius, the high curvature
introduces additional volume, which allows for more conformational freedom. As we see in
Fig 5B, the maximum progressively vanishes with decreasing NP radius, indicating the weaker
crowding effects at higher curvatures (lower radius). This phenomenon is particularly promi-
nent for an AcNP of 10nm radius, where the binding behavior becomes almost linear with
increasing surface coverage.
In Fig 5B we also included an inset with the same data but the number of captured antigen
had been normalized by the area of the nanoparticle. This inset provide information about the
efficiency of binding. Red and black dashed lines in the inset represent the ideal situation of all
the antibodies bound to two or one antigen respectively. We can observe that AcNP with
smaller diameters tend to be more efficient in capturing antigen. As we mentioned before, this
is a consequence of the increment in curvature that provides more available volume and then
less entropic penalty to the binding.
b) Antibody conjugated NP having antibodies bound through biotin/
streptavidin
We have also investigated a system consisting of an AcNP with antibodies conjugated through
a streptavidin/biotin bond. This system is particularly interesting due to its many biomedical
applications [8]. In spite of the strength of the streptavidin-biotin binding (Kd~10−14 M), this
ligand-receptor equilibrium has a quite different behavior on nano-scale surfaces [25]. This
fact is oftentimes overlooked in experimental design considerations where the strong bond is
frequently assumed to be permanent. Then, we address the main differences between the pre-
viously studied system (an AcNP with covalently bound antibodies) and an AcNP with strepta-
vidin-biotin bound antibodies. We consider similar experimental conditions, but we should
note that this system have more species in solution due to an additional ligand-receptor equi-
librium (biotin-streptavidin). The equilibrium concentrations in solution for each species are
calculated based on the initial concentration of antibody and antigen.
Fig 6 shows the number of bound antibody-antigen pairs on the AcNP as a function of the
number of bound antibodies on surface (biotinylated antibodies-streptavidin) for a bulk solu-
tion initially containing 10 pM antibody and 20 pM antigen (upper panels, Fig 6A and 6B) and
a bulk mix initially containing 100 nM of antibody and 200 nM antigen (lower panels, Fig 6C
and 6D), respectively. We have evaluated two spacer chain lengths: 50 monomers (left panels,
Fig 6A and 6C) and no spacer (right panels, Fig 6B and 6D), and considered 3 different anti-
body-antigen dissociation constants (different color lines). Fig 6 illustrates the complexity of
the binding on streptavidin-modified AcNPs. A general feature, similar to the behavior
described for covalent conjugation (Fig 2), is the non-monotonic antigen-antibody binding on
the NP surface. When the number of antibodies on the surface increases, the number of bound
Behavior of ligand binding assays with crowded surfaces
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antigens displays a maximum, as a result of the entropic penalty of reorganization in a
crowded surface.
Conjugation through streptavidin-biotin binding requires a completely different way to
optimize the surface from that used with covalent conjugation (Fig 2). For a bulk solution pre-
pared with low concentrations of the unbound species (10 pM of antibody and 20 pM of anti-
gen; Fig 6A and 6B), we can observe that the amount of bound antigen is almost negligible.
Under these conditions, even AcNPs having high affinity cannot bind considerable numbers
of antigens (red line, Fig 6B). The addition of a spacer to the biotin-antibody system improves
the amount of bound antibody-antigen on the streptavidin modified NP. This binding, how-
ever, is still on the order of a single bound pair, significantly lower than the binding achieved
Fig 6. Captured antigen as a function of the antibody surface coverage on AcNP conjugated through streptavidin/biotin.
The different colors represent different antibody-antigen Kd values. A) Bulk mix concentration = 20 pM antigen/10 pM antibody and
spacer of 50 monomers. B) Bulk mix concentration = 20 pM antigen/10 pM antibody and no spacer. C) Bulk mix concentration = 200
nM antigen/100 nM antibody and spacer of 50 monomers. D) Bulk mix concentration = 200 nM antigen/100 nM antibody and no
spacer.
https://doi.org/10.1371/journal.pone.0185518.g006
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with the covalent conjugation architecture under similar conditions (Fig 2). This behavior is
an important feature of this system that will condition the detection limit in LBAs. Antigen
concentrations below picomolar levels can hardly be detected.
For a bulk solution prepared with relatively higher concentrations of the unbound species
(200 nM of antigen and 100 nM of antibody; Fig 6C and 6D), binding depends almost linearly
on antibody coverage when antigen affinity is high (Kd = 10−11 M). At weaker binding affini-
ties, the capturing capability displays a maximum as antibody coverage increases. Note that
both the system with and without a spacer shows such behavior. The main difference between
these two situations is the enhancement and shift to higher surface coverage of the maxima for
the system with the spacer. This is substantially different from the behavior observed in Fig 2
for the covalent modified AcNP where the addition of the spacer produces the non-monotonic
behavior. Similarly to what occurs at low antigen concentration, the major difference between
these two conjugation schemes is that the total number of captured antigens is much smaller
using the streptavidin conjugation scheme (for high antigen concentration, compare Fig 6C
and 6D with Fig 2C and 2D).
As previously mentioned, our theory provides molecular information about the species that
are bound to the AcNP. In Fig 7, we show how the different antibody species (unbound,
bound to one antigen, bound to two antigens) occupy the surface as a function of the number
of streptavidin binding units for a low (Kd = 10-9M, panel A) and high Kd (Kd = 10-11M, panel
B). These results correspond to antibodies bearing a spacer (50 monomers) and a bulk concen-
tration resulting from mixing 200 nM of antigen with 100 nM of antibody.
In that figure (Fig 7), we observe the formation of a plateau at high streptavidin surface cov-
erage, which corresponds to the limiting number of antibodies on surface observed in Fig 6.
Adding more streptavidin in this plateau region does not increase the number of antibodies on
surface. Due to crowding effects, an important number of the antibodies on surface are
unbound at low Kd (black line in Fig 7A). The dominant species, however, is antibodies
bound to one antigen. Under these conditions, antibodies with two antigens are not present
on the surface, due to high volume that they occupy. Namely, the small decrease in binding
free energy is not sufficient to counterbalance the large entropic cost of surface reorganization
upon capturing two antigens. When the strength of the antibody-antigen interaction increases
(Fig 7B Kd = 10-11M) antibodies with one antigen are the only species on the surface. This
result explains why in Fig 6 we observe a linear binding behavior with antibody coverage for
Kd = 10-11M.
Interestingly, stronger antibody-antigen affinity results in slightly fewer antibodies on the
surface (compare dashed lines curves for both panels of Fig 7). However, antigen-capture
increases with affinity (see also Fig 6C). This is a clear example of how the surface, due to the
presence of the streptavidin-biotin chemical equilibrium, can optimize the surface coverage to
increase the free energy gain associated with the binding equilibriums and reduce the entropic
cost arising from crowding.
If we consider the average position of the center of mass of the antibodies in the streptavidin
AcNP (see S1 Text), the results show less complexity than those of covalently conjugated anti-
bodies. The possibility of self-regulating antibody coverage when using streptavidin conjuga-
tion implies that increasing surface coverage does not have a high impact on the possible
conformations. Then, the average center of mass position remains approximately the same
when increasing streptavidin coverage for the different antibody species. Antibodies with two
antigens have the most extended conformations. However, this bulky molecule is nearly absent
from the surface (see Fig 7). Unbound antibodies remain the least extended conformation,
while the conformations of antibodies with one antigen are slightly extended to account for
the antigen volume.
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Fig 7. Streptavidin/biotin AcNP. Amount of antibody unbound (0 ant.), antibody bound to one antigen (1
ant.), antibody bound to two antigens (2 ant.) and total antibody (total) on surface as a function of the
streptavidin surface coverage. A) Bulk mix concentration = 200 nM antigen/100 nM antibody, spacer 50
monomers, Kd = 10−9 M. B) Bulk mix concentration = 200 nM antigen/100 nM antibody, spacer 50 monomers,
Kd = 10−11 M.
https://doi.org/10.1371/journal.pone.0185518.g007
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Next we analyze the impact of antigen/antibody bulk concentration and nanoparticle radius
on the number of bound antibody-antigen pairs on the AcNP. Fig 8 shows the amount of cap-
tured antigen as function of streptavidin coverage, for an AcNP with antibodies having a
50-monomer spacer and Kd = 10-9M, at different bulk concentrations (Fig 8A) and different
AcNP radius (Fig 8B). In Fig 8A, we see that increasing the concentration of the bulk species
enhances antibody-antigen binding. Antigen capture displays a roughly linear behavior as
function of the surface coverage. This is particularly different from what we observe in the sys-
tem with covalently bonded antibodies, where increasing bulk concentration leads to a more
pronounced non-monotonic behavior (Fig 5A), which results from balancing ligand-receptor
binding and the conformational constraints of accommodating bulky molecules. The surface
of the streptavidin AcNP can reorganize and regulate the number of adsorbed antibodies as a
result of the additional ligand-receptor equilibrium. Then, as we increase the bulk concentra-
tion binding rises but the non-monotonic behavior is less pronounced. Note that the maxi-
mum amount of antibody on the surface (end-point of the binding curves) is approximately
the same independently of bulk concentration. This suggests that despite the increment in the
chemical potential of the solution species, the surface can only accommodate so many
antibodies.
Now we consider the impact of nanoparticle size on the number of bound antibody-antigen
pairs. In the covalently modified system, the radius of the AcNP has a large impact in the bind-
ing behavior, with a vanishing non-monotonic behavior for small radius (Fig 5B). A similar
feature is observed in the streptavidin conjugated AcNP, as seen in Fig 8B that shows antigen
binding for different nanoparticle radius. This dependence on size is due to the effect that cur-
vature has on the available volume to accommodate bulky molecules near the surface. A high
curvature (small radius) results in more available volume for the spacer-antibody to sample
conformational space and bind at different distances from the surface, which reduces the criti-
cality in the balance between binding and crowding, thus diminishing the non-monotonical
behavior. Fig 8B also shows that the number of bound antibody-antigen pairs is higher for
larger AcNP due to the larger surface area.
In Fig 8B we also included an inset with the same data but the number of captured antigen
had been normalized by the area of the nanoparticle. This inset provide information about the
efficiency of binding. Red and black dashed lines in the inset represent the ideal situation of all
the antibodies bound to two or one antigen respectively. We can observe that AcNP with
smaller diameters tend to be more efficient in capturing antigen. As we mentioned before, this
is a consequence of the increment in curvature (smaller diameters) that provides more avail-
able volume and then less entropic penalty to the binding. Is interesting to note that the differ-
ence with Fig 5B inset is that in this system (Fig 8B inset) the binding barely exceeds the ideal
behavior of one antigen per antibody (black dashed line). This behavior is again a manifesta-
tion of the extra degree of freedom that the streptavidin/biotin bond provides to compensate
for the entropic penalty due to crowding.
Discussion and conclusion
In this work we have presented a set of results to shed light into the behavioral complexity of
the ligand-receptor binding of voluminous ligands in crowded surfaces. In particular, we have
analyzed the case of antibody conjugated nanoparticles (AcNP) since antibodies are large
ligands of utmost importance in biomedical applications. We have mainly focused on under-
standing the non-monotonic behavior observed in the ligand-receptor pair formation as a
function of surface coverage, which has been reported in several experimental works [15–20].
For this purpose, we used a molecular theory that has been successfully applied to study similar
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Fig 8. Captured antigen per unit area as a function of antibody surface coverage. Streptavidin conjugated AcNP, spacer 50
monomers, Kd = 10−9 M. A) For different antigen bulk concentrations. AcNP radius = 50 nm. B) For different AcNP radius. Inset in
panel B) are same data but the captured antigen normalized by the area of the NP. Red and black dashed lines, in the inset,
represent the ideal situation of all the antibodies bound to two or one antigen respectively. Bulk concentration mix = 100 nM antibody:
200nM antigen. Triangle symbols represent the set of conditions used in this paper for the rest of the calculations.
https://doi.org/10.1371/journal.pone.0185518.g008
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systems [22–26] showing good agreement with experimental results. Using this approach, we
have explored two different systems: an AcNP with antibodies covalently bonded to its surface,
and an AcNP with antibodies bound using the highly specific streptavidin-biotin interaction.
Our calculations have explored the binding behavior of these systems varying the bulk solution
concentration, antibody-antigen affinity, the inclusion of a polymer spacer, and the radius of
the nanoparticle. The main result we report is a very complex ligand-receptor binding behav-
ior, which strongly depends on the competition between binding and molecular reorganiza-
tion on the surface due to the crowding effect introduced by the volume occupied by the large
ligand (antibody) and ligand-receptor pair (antibody-antigen).
For AcNPs conjugated through covalent bonds with no spacer, our calculations show that
binding has a linear behavior at low surface coverage to then reach a plateau at high coverage.
This behavior is similar observations of Saha et al. [19] in their experimental work. An impor-
tant difference is that in those experiments the antibodies were immobilized at random orien-
tations while in our calculation antibodies are anchored to the surface through the Fc-domain.
Besides these differences in architecture, both systems display similar behavioral features (Fig
2D and Fig 2 from [19]), suggesting that crowding of the surface is one of the major factors
affecting AcNP binding. The inclusion of a spacer greatly improves the amount of bound
ligand-receptor pairs. At the same time, inclusion of a spacer results in a more pronounced
non-monotonic behavior (maxima in Fig 2). These results are consistent with the findings of
Brogan et al. [16] showing that the addition of a spacer on a Fab-fragment conjugated NP
increases the amount of bound pairs. In addition, Brogan et al. showed that there is a maxi-
mum in the capturing capability as a function of the surface coverage of Fab-fragments.
Regarding solution conditions, increasing antigen bulk concentration significantly shifts
the position of maximum binding to higher surface coverage. For AcNP and LBA design, this
implies that the number of large ligands that decorate the surface must be appropriately chosen
depending on bulk receptor concentration. Signal detection for in-vitro applications will have
high variability depending on environment composition. Regarding size, small AcNPs give a
linear behavior that eliminates the uncertainties associated with finding the optimal conditions
for binding. However, the total amount of bound pairs is substantially higher in larger AcNPs.
Thus, given the maximum NP size associated with particular application constraints, the
design of covalently modified AcNP with optimal binding properties will likely require dealing
with the complications of non-monotonic behavior.
Our theory provides information about molecular organization. Although antibodies can-
not detach from the covalently modified architecture, the AcNP can reorganize the surface
optimizing the number of bound antigens and the configuration of the spacer-antibody. We
predict that antibodies with two antigens, due to a volume constraint, are only possible at very
low surface coverage. Antibodies with a single bound antigen represent the most important
contribution to the total number on the surface. In the plateau region, increasing the surface
coverage results in the mere addition of unbound antibodies. The maximum in the binding
capability occurs at the transition between collapsed and stretched conformations of the
spacer.
AcNPs with streptavidin-biotin conjugation present very different behavior from their
covalent counterpart. Streptavidin AcNPs are significantly less sensitive at picomolar concen-
trations. The binding behavior of these AcNPs with streptavidin is qualitatively similar with
and without a spacer, although the addition of a spacer substantially increases binding and
shifts the curves to higher surface coverage. We predict that increasing the antibody-antigen
affinity diminishes the non-monotonical behavior, yielding a linear response for the lowest
studied Kd (10-11M). An interesting feature in the behavior of AcNPs conjugated through
streptavidin is the presence of a maximum in the number of antibodies that the nanoparticle
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can accommodate on its surface. After this maximum, increasing the number of streptavidin
binding sites does not modify the number of biotinylated antibodies on the surface. This result
is a clear manifestation of the high entropic cost associated with surface crowding. At high sur-
face coverage, the entropy cost of crowding prevails over the free energy decrease associate
with streptavidin-biotin binding. In other words, at high surface coverage and despite the high
biotin-streptavidin affinity, the system chooses to have some unbound streptavidin on the sur-
face in order not to pay the price of further disrupting the crowded environment, which would
occur upon bringing additional bulky molecules (biotinylated antibody) to the surface. This
behavior has been observed in related systems [15, 36].
Surface reorganization in the AcNP means finding the optimal conditions that yield ther-
modynamic equilibrium, which results from the interplay between the free energy decrease of
binding and the effects of molecular crowding. In the covalently conjugated AcNP, the surface
reorganizes by including different species and by collapsing or stretching the spacer-antibody
units. In the streptavidin AcNP, the surface reorganizes by including different species and by
regulating the number of antibodies on the surface. A transition between collapsed-elongated
configurations does not occur in this latter system. For high antibody-antigen affinities
(Kd = 10-11M), every antibody adsorbed in the streptavidin-AcNP bears a single antigen.
We have also examined the binding behavior as a function of the (bulk) solution concentra-
tions and the radius of the AcNPs. In contrast with the covalently conjugated AcNP, the non-
monotonic behavior of a streptavidin AcNPs is less pronounced as bulk concentrations are
increased. Interestingly, the maximum number on antibodies that can be placed on the surface
is approximately the same independently of the bulk concentration. We predict that the non-
monotonic binding behavior diminishes and eventually vanishes as AcNP radius decreases. A
higher curvature (smaller radius) offers a larger available volume for sampling spacer configu-
rations, thus allowing for binding at different distances from the NP surface. However, for
sensing purposes, larger AcNPs are more relevant because they can capture significantly more
antigen. As a compromise, these large particles display more pronounced non-monotonic
binding behavior and can make the design of experiments more complicated.
In conclusion, we have presented a series of theoretical predictions that can be useful in the
future design of antibody-conjugated nanoparticles for biomedical and sensing applications.
We have addressed the behavior resulting from two different conjugation schemes and pointed
out critical differences between them. Our results have been presented in terms of normalized
quantities to facilitate extrapolation to other similar systems. One of the noteworthy features
of AcNPs is the non-monotonic binding behavior (maximum) resulting from the competition
between the antigen-antibody (and streptavidin-biotin) binding and the entropic costs of sur-
face reorganization to prevent steric repulsions under the crowded nano-environment that
these large glycoproteins impose.
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